New Frontiers: Research Advances for High-Risk and Advanced Prostate Cancer
Beyond imaging and genetic testing, several distinct lines of research reported in 2026 are reshaping how doctors think about high-risk […]
Blog
The Genetic Turn: PARP Inhibitors Move Earlier in Prostate Cancer Treatment
One of the most consequential developments in prostate cancer research this year has nothing to do with a new drug […]
Seeing and Striking the Target: How PSMA Is Transforming Prostate Cancer Care
Prostate cancer research in 2026 has been defined by a single molecule: PSMA, or prostate-specific membrane antigen. This protein sits […]
July 2026
Includes: Experimental treatment directly kills prostate tumor cells while reawakening antitumor immunity, picnic and awareness events in July,
PARP Inhibitors: Recent Research Advancements in Prostate Cancer (2025–2026)
PARP inhibitors are among the most significant advances in precision medicine for prostate cancer. These drugs work by blocking DNA […]
Two New Approvals, One Clear Direction — Targeted Drug Therapies Come of Age in 2025
The past year brought two significant FDA approvals that signal where prostate cancer treatment is heading: toward more precise, earlier-acting […]
“Smart” Radiation Gets Smarter — Lutetium-177 Therapy Expands Its Reach
A treatment once reserved for men who had exhausted nearly every other option is now available earlier in the course […]
A New Standard in Detection — PSMA PET Imaging Is Changing How We Find Prostate Cancer
For decades, diagnosing and staging prostate cancer relied on a combination of CT scans, bone scans, and MRI. That picture […]
June 2026
Includes: Study finds prostate cancer overdiagnosis rises sharply with age, experimental drug shows promise for patients with advanced prostate cancer,
Help is Available for All Stages of Caregiving
Sandra Scott from Caregivers Alberta helps us reframe what we know about caregivers, giving us stats that show how many there are and the impacts it has on various aspects of our society.